ProfileGDS5678 / 1448727_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 23% 27% 27% 16% 27% 26% 39% 30% 27% 27% 37% 27% 27% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5672523
GSM967853U87-EV human glioblastoma xenograft - Control 22.6251927
GSM967854U87-EV human glioblastoma xenograft - Control 32.6249827
GSM967855U87-EV human glioblastoma xenograft - Control 42.3417816
GSM967856U87-EV human glioblastoma xenograft - Control 52.5720627
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.666826
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9587639
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6648330
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.595727
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6138127
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.844237
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5980727
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.627227
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6135827